• Skip to main content
  • Skip to secondary menu
  • Skip to footer

Press Media Release

press release distribution

  • Submit a Press Release
  • Market Wire
  • Make a Contribution
  • About
    • Template for press/media release
    • How to structure your press release for maximum impact
    • Crafting effective headlines and leads to capture journalists’ attention
    • Understanding the dos and don’ts of writing press releases
    • Tips for writing clear, concise, and informative press releases
    • The importance of understanding your audience before writing a press release
    • Best practices for incorporating quotes and statistics in your press release
    • Writing effective boilerplates and about us sections for press releases
    • Identifying key media contacts and building relationships with journalists
    • Writing for different types of media, such as print, online, and social media
    • Measuring the success of your press release and tracking media coverage
  • Contact
    • GDPR

Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19

November 21, 2020 By admin Leave a Comment

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for casirivimab and imdevimab to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID-19. This includes those who are 65 years of age or older or who have certain chronic medical conditions.

In a clinical trial of patients with COVID-19, casirivimab and imdevimab, administered together, were shown to reduce COVID-19-related hospitalization or emergency room visits in patients at high risk for disease progression within 28 days after treatment when compared to placebo. The safety and effectiveness of this investigational therapy for use in the treatment of COVID-19 continues to be evaluated.

Casirivimab and imdevimab must be administered together by intravenous (IV) infusion.

Casirivimab and imdevimab are not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19. A benefit of casirivimab and imdevimab treatment has not been shown in patients hospitalized due to COVID-19. Monoclonal antibodies, such as casirivimab and imdevimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation.

“The FDA remains committed to advancing the nation’s public health during this unprecedented pandemic. Authorizing these monoclonal antibody therapies may help outpatients avoid hospitalization and alleviate the burden on our health care system,” said FDA Commissioner Stephen M. Hahn, M.D. “As part of our Coronavirus Treatment Acceleration Program, the FDA uses every possible pathway to make new treatments available to patients as quickly as possible while continuing to study the safety and effectiveness of these treatments.”

Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens such as viruses. Casirivimab and imdevimab are monoclonal antibodies that are specifically directed against the spike protein of SARS-CoV-2, designed to block the virus’ attachment and entry into human cells.

“The emergency authorization of these monoclonal antibodies administered together offers health care providers another tool in combating the pandemic,” said Patrizia Cavazzoni, M.D., acting director of the FDA’s Center for Drug Evaluation and Research. “We will continue to facilitate the development, evaluation and availability of COVID-19 therapies.”

The issuance of an EUA is different than an FDA approval. In determining whether to issue an EUA, the FDA evaluates the totality of available scientific evidence and carefully balances any known or potential risks with any known or potential benefits of the product for use during an emergency. Based on the FDA’s review of the totality of the scientific evidence available, the agency has determined that it is reasonable to believe that casirivimab and imdevimab administered together may be effective in treating patients with mild or moderate COVID-19. When used to treat COVID-19 for the authorized population, the known and potential benefits of these antibodies outweigh the known and potential risks. There are no adequate, approved and available alternative treatments to casirivimab and imdevimab administered together for the authorized population.

The data supporting this EUA for casirivimab and imdevimab are based on a randomized, double-blind, placebo-controlled clinical trial in 799 non-hospitalized adults with mild to moderate COVID-19 symptoms. Of these patients, 266 received a single intravenous infusion of 2,400 milligrams casirivimab and imdevimab (1,200 mg of each), 267 received 8,000 mg casirivimab and imdevimab (4,000 mg of each), and 266 received a placebo, within three days of obtaining a positive SARS-CoV-2 viral test.

The prespecified primary endpoint for the trial was time-weighted average change in viral load from baseline. Viral load reduction in patients treated with casirivimab and imdevimab was larger than in patients treated with placebo at day seven. However, the most important evidence that casirivimab and imdevimab administered together may be effective came from the predefined secondary endpoint of medically attended visits related to COVID-19, particularly hospitalizations and emergency room visits within 28 days after treatment. For patients at high risk for disease progression, hospitalizations and emergency room visits occurred in 3% of casirivimab and imdevimab-treated patients on average compared to 9% in placebo-treated patients. The effects on viral load, reduction in hospitalizations and ER visits were similar in patients receiving either of the two casirivimab and imdevimab doses.

Under the EUA, fact sheets that provide important information about using casirivimab and imdevimab administered together in treating COVID-19 as authorized must be made available to health care providers and to patients and caregivers. These fact sheets include dosing instructions, potential side effects and drug interactions. Possible side effects of casirivimab and imdevimab include: anaphylaxis and infusion-related reactions, fever, chills, hives, itching and flushing.

The EUA was issued to Regeneron Pharmaceuticals Inc.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

SOURCE U.S. Food and Drug Administration
http://www.fda.gov

Filed Under: Press Release

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Footer

Recent Posts

  • Explore the Future of Silicone Technology with Trelleborg at Silicone Expo
  • U.S. Conference of Mayors Continues to Stand with Ukraine
  • Junevity’s Pioneering RESET Platform Garners $10 Million Seed Investment to Transform Age-Related Disease Treatment
  • Festive Splendor: Christmas Market Magic in Vienna
  • The Art of the Photo Press Release
  • The Future of Press Release Distribution
  • Local vs. Global Press Release Distribution
  • Crafting the Perfect Distribution Schedule
  • Common Mistakes in Press Release Distribution
  • Press Releases: A Cost-Effective Marketing Tool

Media Partners

  • Press Club US
  • ZGM.org: Zeitgeist Generative Media
  • MSL.net: Media Sharing Lab
  • Policymaker.net
U.S. Response Inadequate as Houthi Attacks on Ships in the Red Sea Disrupt Global Maritime Shipping
Biden-Harris Campaign 2024 Commits $1.5 Million Advertising Buy with the Black Press of America
Boeing to Plead Guilty to Fraud in Fatal 737 MAX Crashes: Ramifications for the Aerospace Giant
FOX News Media's Simulcast of CNN Presidential Debate Dominates Television with 13.4 Million Viewers
National Police Association Asks U.S. Supreme Court to Protect Police Officers from Abusive Inclusion on Brady or Giglio Lists by Requiring Due Process
UN Panel: Wall Street Journal Reporter Arbitrarily Detained By Russia
Tortured by Hamas
National Survey Reveals Financial Struggles Among Middle-Income Families Despite Slight Improvement in Purchasing Power
A Progressive Shift in Pentagon Media Relations
About
The Cultural Significance of Food in Different Societies
Unleashing Imagination: Exploring Generative Media's Impact on Digital Storytelling and Narrative Formats
Amplifying Voices: Generative Media's Role in Digital Activism and Social Justice
The Impact of Virtual Reality on Education: Enhancing Learning in the Digital Age
The Rise of Side Hustle Culture: Navigating the New World of Multifaceted Careers
The Enigma Chronicles: Whispers of the Ether
With Possible Strike Looming, Day Care Workers Deliver Solidarity Petition but Management Nowhere to Be Found
Evolution of Clean: Conceptualizing the AI-Powered Vacuum Cleaner
Why Plants Can't Thrive in a 100% Carbon Dioxide Environment
Embrace the Tech Revolution: Don't be afraid to experiment with new tools
Video Game Voice Actors Authorize Strike, Ahead of Contract Negotiations
The Evolving Landscape of Cybersecurity Events
About
Canva to Acquire Generative AI Platform Leonardo.AI to Bring Leading Visual AI to Every Organization
Fed Expected to Hike Rates Again, Then Hold
Scientific American Wins Seven Telly Awards
Charting the Erasmus: Mapping Blackthorne's Odyssey in Clavell's Shogun
Savers Grapple with Inflation and Asset Declines
Sponsored Post
Genus AI Secures $6 Million in Seed Round Extension, Totaling $11 Million in Funding to Revolutionize E-commerce with Generative AI
The Druze community in Syria protests Hezbollah after the Majdal Shams massacre
Meetup Policymaker 2024: Innovating Governance
Improving Treatment Access for Havana Syndrome: GAO Report Highlights Communication and Monitoring Gaps in DOD Response
The Majdal Shams tragedy is the result of the weak Biden and Harris administration
Contact
Hungarian Prime Minister Viktor Orban's Policies: A Threat to European Unity and Regional Solidarity
The Decline of Integrity: How the New York Times and BBC Have Lost Their Moral Compass
Maduro thugs stealing the election in Venezuela
Former Bush Counsel Urges Kamala Harris to Consider Influential Hispanics for Vice Presidential Pick
Venezuela Election Fraud

Media Partners

  • Media Presser
  • 3V.org: PR/Media Agency
  • Publishing House
  • Media Instances
S3H.com Launches to Provide Comprehensive Technology Solutions
Ukrainian Military Performance and Outlook
Iran proposes amendments to a draft resolution on dark shipping at the upcoming meeting of the International Maritime Organization (IMO)
SurveyMonkey announces international availability of AI-generated surveys
Posters.org Announces Workshop on Designing Impactful Conference Posters
Silent Night (2023) Official Trailer
COP28 Event Hosted by KHNP Highlights Nuclear Energy's Crucial Role in a Carbon-Free Future
MarketAnalysis.com Releases Groundbreaking Market Research Report on Custom Photography Apps
MIT Technology Review to host free virtual event honoring 2023 Innovators Under 35
San Francisco Thought Leader Predicts That Government Turmoil and Disruption is Likely to Continue in 2024
Andy Murray: A Legacy of Tenacity and Triumph in Tennis
Go Visual: Elevate Your Storytelling with Compelling Imagery
Hustle Your Story
Disney+ Subscribers Can Now Explore Iceland's Thingvellir National Park with Apple Vision Pro
Empowering Small Businesses: How MktgDev.com Transforms Marketing Strategies
Bahrain International Airshow 2024 Registration Now Live
Storytelling is Everything
MarketAnalysis.com Releases Comprehensive Report on the Impact of Artificial Intelligence on the Accounting Profession
ASOM-Net reduces TCO with Smartoptics 400G disaggregated networking
About
Xi Jinping and the CCP Are Driving China's Economy into the Ground
Generative AI Investment to Grow 28%, Promising High Returns for Early Adopters
Google is set to acquire the Israeli cybersecurity startup Wiz for $23 billion
The Timeless Charm of Old Libraries
Nikki Haley as VP Pick: Strategic Choice for a Diverse and Forward-Thinking Republican Ticket
USCENTCOM Neutralizes Multiple Houthi Threats in the Red Sea
Sponsored Post
Celebrating Liberty: The Vibrant Spirit of Bastille Day
My Sicilian Adventures: Capturing Moments with the Canon R50
Gender disparities across various aspects of life in Africa
Crafting Your Path to Social Influencer Success
Wild boars in the city
Disrespectful, noninclusive, unethical, cutthroat, and abusive
Voyage Beyond Realms: Deciphering the Enigmatic Tapestry of ‘Echoes from Eternity’
Too many containers
Media Tycoons: The Powers Behind the Scenes
If you want to support IsraelNews.org, click the link below
Case Study: Navigating Change: Transforming “Brands To Shop” into a Sustainable Fast Fashion Leader
Shielding the Shot: The Art of Outdoor Camera Setups
Sister Cities of San Francisco

Copyright © 2022 PressMediaRelease.com

Sponsored by Exclusive Domains